[go: up one dir, main page]

HUP9904287A1 - Acelluláris pertussis vakcina diftéria- és tetanusz-toxoidokkal - Google Patents

Acelluláris pertussis vakcina diftéria- és tetanusz-toxoidokkal

Info

Publication number
HUP9904287A1
HUP9904287A1 HU9904287A HUP9904287A HUP9904287A1 HU P9904287 A1 HUP9904287 A1 HU P9904287A1 HU 9904287 A HU9904287 A HU 9904287A HU P9904287 A HUP9904287 A HU P9904287A HU P9904287 A1 HUP9904287 A1 HU P9904287A1
Authority
HU
Hungary
Prior art keywords
tetanus
antigens
pertussis
toxoids
diphtheriae
Prior art date
Application number
HU9904287A
Other languages
English (en)
Inventor
Patrick Florent
Jean Stephenne
Christian Vandecasserie
Original Assignee
Smithkline Beecham Biologicals S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Biologicals S.A. filed Critical Smithkline Beecham Biologicals S.A.
Publication of HUP9904287A1 publication Critical patent/HUP9904287A1/hu
Publication of HUP9904287A3 publication Critical patent/HUP9904287A3/hu
Publication of HU224126B1 publication Critical patent/HU224126B1/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0016—Combination vaccines based on diphtheria-tetanus-pertussis
    • A61K39/0018—Combination vaccines based on acellular diphtheria-tetanus-pertussis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/099—Bordetella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K2039/10—Brucella; Bordetella, e.g. Bordetella pertussis; Not used, see subgroups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

A találmány tárgya diftéria, tetanűsz és pertűssis antigénekettartalmazó vakcinakőmpőzíció, amely az egyes antigéneket: a diftériatőxőidőt (D), tetanűsz tőxőidőt (T), pertűssis tőxint (PT), rőstőshemagglűtinint (FHA) és pertaktint (69K) alacsőny dózisbantartalmazza. A találmány szerinti vakcina képes a pertűssismegelőzésére, miközben rendkívül alacsőny reaktőgenicitást műtat. Atalálmány tárgyát képezik tővábbá azők a vakcinakőmpőzíciók, amelyek afentieken kívül tővábbi antigéneket is tartalmaznak. ŕ
HU9904287A 1996-11-07 1997-11-04 Acelluláris pertussis vakcina diftéria- és tetanusz-toxoidokkal HU224126B1 (hu)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9623233.5A GB9623233D0 (en) 1996-11-07 1996-11-07 Vaccine composition
PCT/EP1997/006180 WO1998019702A1 (en) 1996-11-07 1997-11-04 Acellular pertussis vaccine with diphthriae- and tetanus-toxoids

Publications (3)

Publication Number Publication Date
HUP9904287A1 true HUP9904287A1 (hu) 2000-04-28
HUP9904287A3 HUP9904287A3 (en) 2001-05-28
HU224126B1 HU224126B1 (hu) 2005-05-30

Family

ID=10802615

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9904287A HU224126B1 (hu) 1996-11-07 1997-11-04 Acelluláris pertussis vakcina diftéria- és tetanusz-toxoidokkal

Country Status (30)

Country Link
EP (2) EP1240905B3 (hu)
JP (1) JP3980652B2 (hu)
KR (1) KR100518044B1 (hu)
CN (1) CN1130226C (hu)
AR (1) AR011509A1 (hu)
AT (2) ATE222773T1 (hu)
AU (1) AU710475B2 (hu)
BR (2) BRPI9712917B8 (hu)
CA (1) CA2271008C (hu)
CO (1) CO4910171A1 (hu)
CY (2) CY2407B1 (hu)
CZ (1) CZ295954B6 (hu)
DE (3) DE69733285T3 (hu)
DK (2) DK0941117T3 (hu)
ES (2) ES2182131T3 (hu)
GB (1) GB9623233D0 (hu)
HK (1) HK1050473B (hu)
HU (1) HU224126B1 (hu)
IL (1) IL129530A (hu)
LU (1) LU91183I2 (hu)
NO (2) NO320186B1 (hu)
NZ (1) NZ335384A (hu)
PL (1) PL188460B1 (hu)
PT (2) PT1240905E (hu)
SA (1) SA98181128B1 (hu)
SI (2) SI0941117T1 (hu)
TR (1) TR199900979T2 (hu)
TW (1) TW471971B (hu)
WO (1) WO1998019702A1 (hu)
ZA (1) ZA979984B (hu)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1004314A1 (fr) * 1998-11-26 2000-05-31 Pasteur Merieux MSD Vaccin T.d. Polio rappel pour une population vaccinée ou sensibilisée
KR100374813B1 (ko) * 2000-04-07 2003-03-03 녹십자백신 주식회사 디프테리아, 파상풍 톡소이드, 정제백일해 및비형간염표면항원을 포함한 4가 혼합백신 및 그 제조 방법
GB0108364D0 (en) * 2001-04-03 2001-05-23 Glaxosmithkline Biolog Sa Vaccine composition
KR100401423B1 (ko) * 2001-01-10 2003-10-17 주식회사 엘지생명과학 혼합 백신의 제조 방법
JP5007425B2 (ja) * 2006-01-30 2012-08-22 財団法人ヒューマンサイエンス振興財団 百日咳ワクチンの安全性評価方法
GB0616306D0 (en) * 2006-08-16 2006-09-27 Novartis Ag Vaccines
GB0822633D0 (en) * 2008-12-11 2009-01-21 Novartis Ag Formulation
US9950062B2 (en) 2009-09-02 2018-04-24 Glaxosmithkline Biologicals Sa Compounds and compositions as TLR activity modulators
CN103313725B (zh) 2010-09-01 2016-06-29 诺华有限公司 免疫增强剂吸附不溶性金属离子
CA2828844C (en) 2011-03-02 2020-07-14 Novartis Ag Combination vaccines with lower doses of antigen and/or adjuvant
CN102363041A (zh) * 2011-11-17 2012-02-29 成都欧林生物科技股份有限公司 不含防腐剂疫苗的制作工艺
MX372965B (es) * 2012-03-08 2020-04-01 Glaxosmithkline Biologicals Sa Formulaciones adyuvadas de vacunas de difteria, tetanos y tos ferina (dtp) de refuerzo.
CN102793915B (zh) * 2012-07-25 2013-10-23 天津康希诺生物技术有限公司 一种无细胞百日咳疫苗的生产方法
AU2013301312A1 (en) 2012-08-06 2015-03-19 Glaxosmithkline Biologicals S.A. Method for eliciting in infants an immune response against RSV and B. pertussis
US20140037680A1 (en) 2012-08-06 2014-02-06 Glaxosmithkline Biologicals, S.A. Novel method
CN103100081A (zh) * 2012-12-26 2013-05-15 天津康希诺生物技术有限公司 一种多价联合疫苗
EP2863943B1 (en) 2013-03-08 2016-07-13 Crucell Holland B.V. Acellular pertussis vaccine
KR20160040290A (ko) 2013-08-05 2016-04-12 글락소스미스클라인 바이오로지칼즈 에스.에이. 조합 면역원성 조성물
CN114748616A (zh) * 2022-05-23 2022-07-15 中国医学科学院医学生物学研究所 一种成人青少年用无细胞百白破联合疫苗及其制备方法
CN117417419B (zh) * 2023-01-10 2024-04-19 康希诺生物股份公司 一种百日咳毒素脱毒方法及无细胞百白破联合疫苗
CN119524117B (zh) * 2025-01-23 2025-09-23 康希诺生物股份公司 免疫原性组合物、百白破联合疫苗及其制备方法和应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI861417A0 (fi) 1985-04-15 1986-04-01 Endotronics Inc Hepatitis b ytantigen framstaelld med rekombinant-dna-teknik, vaccin, diagnostiskt medel och cellinjer samt foerfaranden foer framstaellning daerav.
US4895800A (en) 1985-11-26 1990-01-23 Phillips Petroleum Company Yeast production of hepatitis B surface antigen
ZA88488B (en) 1987-01-30 1988-10-26 Smith Kline Rit Hepatitis b virus surface antigens and hybrid antigens containing them
EP1088830A3 (en) 1987-06-22 2004-04-07 Medeva Holdings B.V. Hepatitis b surface antigen particles
DE3789866T2 (de) 1987-07-17 1994-09-22 Rhein Biotech Gesellschaft Fuer Neue Biotechnologische Prozesse Und Produkte Mbh, 40595 Duesseldorf DNA-Moleküle, die für FMDH-Kontrollabschnitte und Strukturgene für ein Protein mit FMDH-Aktivität kodieren, sowie deren Anwendung.
SG48175A1 (en) 1989-07-25 1998-04-17 Smithkline Beecham Biolog Novel antigens and method for their preparation
GB9007024D0 (en) 1990-03-29 1990-05-30 Imperial College Novel vaccine
RU2160120C2 (ru) * 1992-05-23 2000-12-10 Смитклайн Бичам Байолоджикалс С.А. Комбинированная вакцина на основе поверхностного антигена вируса гепатита в, способ ее получения и способ предупреждения инфекции гепатита в у человека

Also Published As

Publication number Publication date
BRPI9712917B8 (pt) 2021-05-25
DK1240905T5 (da) 2010-01-11
CO4910171A1 (es) 2000-04-24
DK1240905T3 (da) 2005-07-18
CZ164099A3 (cs) 1999-10-13
IL129530A (en) 2005-11-20
EP1240905B3 (en) 2009-08-26
WO1998019702A1 (en) 1998-05-14
PL188460B1 (pl) 2005-02-28
NO2006005I2 (no) 2010-04-12
HK1050473B (en) 2006-03-03
JP2001503422A (ja) 2001-03-13
ES2240647T3 (es) 2005-10-16
CY2568B1 (en) 2008-07-02
EP0941117A1 (en) 1999-09-15
CN1236321A (zh) 1999-11-24
CZ295954B6 (cs) 2005-12-14
KR20000053092A (ko) 2000-08-25
BR9712917A (pt) 1999-12-07
NO992156D0 (no) 1999-05-04
SA98181128B1 (ar) 2006-03-25
KR100518044B1 (ko) 2005-09-30
NO320186B1 (no) 2005-11-07
CA2271008A1 (en) 1998-05-14
TW471971B (en) 2002-01-11
TR199900979T2 (xx) 1999-07-21
DE122005000046I1 (de) 2005-12-29
ES2182131T3 (es) 2003-03-01
HU224126B1 (hu) 2005-05-30
DK0941117T3 (da) 2002-11-18
DE69715031D1 (de) 2002-10-02
NO2006005I1 (no) 2006-05-08
EP0941117B1 (en) 2002-08-28
JP3980652B2 (ja) 2007-09-26
PT941117E (pt) 2002-12-31
GB9623233D0 (en) 1997-01-08
IL129530A0 (en) 2000-02-29
ES2240647T7 (es) 2010-03-31
AU5319698A (en) 1998-05-29
DE69733285D1 (de) 2005-06-16
BRPI9712917B1 (pt) 2019-12-03
SI1240905T1 (en) 2005-10-31
DE69733285T3 (de) 2010-03-25
LU91183I2 (fr) 2005-09-20
SI0941117T1 (en) 2002-12-31
ATE295178T1 (de) 2005-05-15
HK1050473A1 (en) 2003-06-27
NZ335384A (en) 2000-10-27
HUP9904287A3 (en) 2001-05-28
HK1022638A1 (en) 2000-08-18
AU710475B2 (en) 1999-09-23
EP1240905A1 (en) 2002-09-18
DE69733285T2 (de) 2006-01-12
AR011509A1 (es) 2000-08-30
CN1130226C (zh) 2003-12-10
ZA979984B (en) 1998-07-23
ATE222773T1 (de) 2002-09-15
PL333127A1 (en) 1999-11-22
NO992156L (no) 1999-05-04
CY2407B1 (en) 2004-09-10
DE69715031T2 (de) 2003-05-08
EP1240905B1 (en) 2005-05-11
CA2271008C (en) 2008-07-22
PT1240905E (pt) 2005-09-30

Similar Documents

Publication Publication Date Title
HUP9904287A1 (hu) Acelluláris pertussis vakcina diftéria- és tetanusz-toxoidokkal
LU91595I2 (fr) Combinaison d'anatoxine diphtérique, d'anatoxine tétanique, d'anatoxine coquelucheuse, d'hémagglutinine filamenteuse, de pertactine et de polyoside capsulaire d'haemophilus influenzae type b (InfanrixHib)
PL351893A1 (en) Vaccines
AU5741001A (en) Epitope synchronization in antigen presenting cells
TR200002930T2 (tr) Kolaylaştırıcı kompozisyonlar
UA40597C2 (uk) Вакцинна композиція,спосіб лікування ссавців, що страждають або сприйнятливі до інфекції, спосіб лікування ссавців, що страждають на рак, спосіб одержання вакцинної композиції, композиція ад'ювантів
MX9304089A (es) Uso de gm-csf como una vacuna adyuvante.
KR890701758A (ko) 재조합 dna에서 유도한 보르데텔라 외독소 소단위체의 유사체 및 그를 포함하는 백신
PT826001E (pt) Vacinas acelulares contra a tosse convulsa e metodos para a sua preparacao
CY1110327T1 (el) DTPa ΕΜΒΟΛΙΑ ΒΛΕΝΝΟΓΟΝΟΥ
OA09863A (en) Use of IL-4 to enhance immune response to immunogens in vaccines.
MY127452A (en) Vaccines.
ATE329615T1 (de) Borrelia burgdorferi bacterin
EP0952771A4 (en) SAPONIN COMPOSITIONS AND THEIR USE
NO913131L (no) Immunogene konjugater av ikke-toksisk oligosakkarid fra bordetella pertussis lipoolysakkarid.
GB9611501D0 (en) Vaccine compositions
MX9708226A (es) Vacunas que contienen una saponina y un esterol.

Legal Events

Date Code Title Description
HFG4 Patent granted, date of granting

Effective date: 20050407